Biomemory has launched DNA Shield, its first commercial managed service designed to store particularly critical data offline in synthetic DNA for decades-long retention independent of active IT systems.
The service is initially offered through an Early Access Program and targets organizations that need a separate, air-gapped layer of protection against cyber attacks, organizational changes, infrastructure migrations, regulatory examinations, advances in artificial intelligence, and quantum computing.
Service Concept and Workflow
DNA Shield creates an offline security layer that is deliberately disconnected from network-accessible attack surfaces. The solution is intended for relatively small volumes of irreplaceable information. Data first passes through a secure onboarding process where the customer selects the material and performs encryption. DNA Shield then encodes the information into synthetic DNA, which is stored under managed physical custody. Recovery is intentionally non-routine and requires a controlled, operator-mediated process rather than self-service access.
Initial Use Cases
- Continuity of key custody: long-term recovery of cryptographic keys even after personnel or provider changes, positioned as a complement to certified hardware security modules.
- Industrial intellectual property: offline copies of proprietary formulations, processes, or design parameters.
- Regulated integrity records: tamper-evident copies proving that critical records have remained unchanged since approval.
- Sovereign storage and golden records: preservation of records intended to outlast the originating systems and organizations.
Company Developments
The product introduction follows two key corporate changes. In March 2026 Biomemory acquired the assets of Catalog Technologies, a Boston-based DNA data storage firm, adding a second production and research site alongside its Paris headquarters. In July 2026 the company appointed Laurent Guengant as CEO, citing his more than 30 years of experience in storage, telecommunications, and energy sectors.
Availability and Roadmap
DNA Shield is currently accessible only via the Early Access Program. It represents the first element of Biomemory’s multi-year Molecular IT roadmap. The company plans to expand the offering to general data storage beginning in 2029, with molecular search and data processing capabilities to follow later.

